Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS), are increasingly recognized as major contributors to the global burden of disease due to their progressive nature and lack of effective long-term treatments [1]. Emerging research has highlighted the gut-brain axis as a key player in neurological health, with the gut microbiota being a critical modulator of neuroinflammation, immune function, and even cognitive processes [2]. Given the rising interest in gut microbiota modulation as a therapeutic strategy, we sought to map the clinical trial landscape in this area, focusing on how probiotics, fecal bacteriotherapy, prebiotics, and other microbiota-related interventions are being evaluated for their potential in managing neurodegenerative diseases.
